154 related articles for article (PubMed ID: 20371719)
1. Natural immunity enhances the activity of a DR5 agonistic antibody and carboplatin in the treatment of ovarian cancer.
El-Gazzar A; Perco P; Eckelhart E; Anees M; Sexl V; Mayer B; Liu Y; Mikulits W; Horvat R; Pangerl T; Zheng D; Krainer M
Mol Cancer Ther; 2010 Apr; 9(4):1007-18. PubMed ID: 20371719
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model.
Bevis KS; McNally LR; Sellers JC; Della Manna D; Londoño Joshi A; Amm H; Straughn JM; Buchsbaum DJ
Gynecol Oncol; 2011 Apr; 121(1):193-9. PubMed ID: 21211830
[TBL] [Abstract][Full Text] [Related]
3. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5.
Adams C; Totpal K; Lawrence D; Marsters S; Pitti R; Yee S; Ross S; Deforge L; Koeppen H; Sagolla M; Compaan D; Lowman H; Hymowitz S; Ashkenazi A
Cell Death Differ; 2008 Apr; 15(4):751-61. PubMed ID: 18219321
[TBL] [Abstract][Full Text] [Related]
4. Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma.
Brincks EL; Kucaba TA; James BR; Murphy KA; Schwertfeger KL; Sangwan V; Banerjee S; Saluja AK; Griffith TS
FEBS J; 2015 Dec; 282(24):4747-4765. PubMed ID: 26426449
[TBL] [Abstract][Full Text] [Related]
5. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.
Hyer ML; Croxton R; Krajewska M; Krajewski S; Kress CL; Lu M; Suh N; Sporn MB; Cryns VL; Zapata JM; Reed JC
Cancer Res; 2005 Jun; 65(11):4799-808. PubMed ID: 15930300
[TBL] [Abstract][Full Text] [Related]
6. Quinacrine induces apoptosis in cancer cells by forming a functional bridge between TRAIL-DR5 complex and modulating the mitochondrial intrinsic cascade.
Das S; Tripathi N; Preet R; Siddharth S; Nayak A; Bharatam PV; Kundu CN
Oncotarget; 2017 Jan; 8(1):248-267. PubMed ID: 27542249
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Importin β1 Augments the Anticancer Effect of Agonistic Anti-Death Receptor 5 Antibody in TRAIL-resistant Tumor Cells.
Kojima Y; Nishina T; Nakano H; Okumura K; Takeda K
Mol Cancer Ther; 2020 May; 19(5):1123-1133. PubMed ID: 32156787
[TBL] [Abstract][Full Text] [Related]
8. Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts.
Daniel D; Yang B; Lawrence DA; Totpal K; Balter I; Lee WP; Gogineni A; Cole MJ; Yee SF; Ross S; Ashkenazi A
Blood; 2007 Dec; 110(12):4037-46. PubMed ID: 17724141
[TBL] [Abstract][Full Text] [Related]
9. A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells.
Petrucci E; Pasquini L; Petronelli A; Saulle E; Mariani G; Riccioni R; Biffoni M; Ferretti G; Benedetti-Panici P; Cognetti F; Scambia G; Humphreys R; Peschle C; Testa U
Gynecol Oncol; 2007 May; 105(2):481-92. PubMed ID: 17292950
[TBL] [Abstract][Full Text] [Related]
10. TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells.
Tuthill MH; Montinaro A; Zinngrebe J; Prieske K; Draber P; Prieske S; Newsom-Davis T; von Karstedt S; Graves J; Walczak H
Oncogene; 2015 Apr; 34(16):2138-2144. PubMed ID: 24909167
[TBL] [Abstract][Full Text] [Related]
11. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells.
Shiraishi T; Yoshida T; Nakata S; Horinaka M; Wakada M; Mizutani Y; Miki T; Sakai T
Cancer Res; 2005 Jul; 65(14):6364-70. PubMed ID: 16024639
[TBL] [Abstract][Full Text] [Related]
12. Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model.
Duiker EW; de Vries EG; Mahalingam D; Meersma GJ; Boersma-van Ek W; Hollema H; Lub-de Hooge MN; van Dam GM; Cool RH; Quax WJ; Samali A; van der Zee AG; de Jong S
Clin Cancer Res; 2009 Mar; 15(6):2048-57. PubMed ID: 19276284
[TBL] [Abstract][Full Text] [Related]
13. Killing of resistant cancer cells with low Bak by a combination of an antimesothelin immunotoxin and a TRAIL Receptor 2 agonist antibody.
Du X; Xiang L; Mackall C; Pastan I
Clin Cancer Res; 2011 Sep; 17(18):5926-34. PubMed ID: 21813632
[TBL] [Abstract][Full Text] [Related]
14. Tanshinone IIA Facilitates TRAIL Sensitization by Up-regulating DR5 through the ROS-JNK-CHOP Signaling Axis in Human Ovarian Carcinoma Cell Lines.
Chang CC; Kuan CP; Lin JY; Lai JS; Ho TF
Chem Res Toxicol; 2015 Aug; 28(8):1574-83. PubMed ID: 26203587
[TBL] [Abstract][Full Text] [Related]
15. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.
Lu M; Strohecker A; Chen F; Kwan T; Bosman J; Jordan VC; Cryns VL
Clin Cancer Res; 2008 May; 14(10):3168-76. PubMed ID: 18483385
[TBL] [Abstract][Full Text] [Related]
16. Depletion of CABYR-a/b sensitizes lung cancer cells to TRAIL-induced apoptosis through YAP/p73-mediated DR5 upregulation.
Xiao Q; Qian Z; Zhang W; Liu J; Hu E; Zhang J; Li M; Wang J; Kong F; Li Y; Wang R; Tan X; He D; Xiao X
Oncotarget; 2016 Feb; 7(8):9513-24. PubMed ID: 26843620
[TBL] [Abstract][Full Text] [Related]
17. Kaempferol Sensitizes Human Ovarian Cancer Cells-OVCAR-3 and SKOV-3 to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis via JNK/ERK-CHOP Pathway and Up-Regulation of Death Receptors 4 and 5.
Zhao Y; Tian B; Wang Y; Ding H
Med Sci Monit; 2017 Oct; 23():5096-5105. PubMed ID: 29070784
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antitumor activity of recombinant human Apo2L/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in combination with carboplatin and pemetrexed in malignant pleural mesothelioma.
Pasello G; Urso L; Silic-Benussi M; Schiavon M; Cavallari I; Marulli G; Nannini N; Rea F; Ciminale V; Favaretto A
J Thorac Oncol; 2014 Jul; 9(7):1008-1017. PubMed ID: 24922007
[TBL] [Abstract][Full Text] [Related]
19. Pro-survival effects by NF-κB, Akt and ERK(1/2) and anti-apoptosis actions by Six1 disrupt apoptotic functions of TRAIL-Dr4/5 pathway in ovarian cancer.
Yang J; Li G; Zhang K
Biomed Pharmacother; 2016 Dec; 84():1078-1087. PubMed ID: 27780136
[TBL] [Abstract][Full Text] [Related]
20. Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistant hepatoma cells to TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of DR5.
Kim H; Kim EH; Eom YW; Kim WH; Kwon TK; Lee SJ; Choi KS
Cancer Res; 2006 Feb; 66(3):1740-50. PubMed ID: 16452234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]